What Roche Canada does

Roche Canada (legal entity Hoffmann-La Roche Limited) is the wholly-owned Canadian subsidiary of F. Hoffmann-La Roche Ltd (SIX: ROG), one of the world's largest biotech companies with a 125-year operating history and Canadian presence since 1931. Headquartered in Mississauga, Ontario with a diagnostics operations office in Laval, Quebec, the company operates two core pillars: (1) Pharmaceuticals, developing and commercializing innovative prescription medicines across oncology, immunology, infectious diseases, neuroscience, and ophthalmology, anchored by brands such as HERCEPTIN, AVASTIN, ACTEMRA, OCREVUS, TECENTRIQ and recent launches ITOVEBI (inavolisib), VABYSMO (faricimab), and TNKase (tenecteplase); and (2) Diagnostics, providing in vitro diagnostic instruments, reagents and consumables spanning clinical chemistry, immunochemistry, molecular diagnostics, hematology, histology, point-of-care testing, and next-generation sequencing. The portfolio is built on proprietary platforms including electrochemiluminescence (ECL) detection technology, the cobas pro/cobas pure integrated solutions, cobas Liat PCR point-of-care system, cobas i 601 mass spectrometry analyzer, and the navify digital solutions suite, with a parallel Diabetes Care franchise under the Accu-Chek and mySugr brands for integrated personalized diabetes management.

The company makes money through three primary revenue streams: pharmaceutical product sales reimbursed via provincial drug programs (Ontario Drug Benefit, pCPA negotiations, Ontario's FAST program), diagnostic instrument placements and recurring reagent/service contracts with hospital and reference laboratories, and hardware plus consumable sales of Accu-Chek glucose meters, test strips, and mySugr digital subscriptions through retail pharmacy and direct-to-patient channels. Go-to-market combines enterprise field sales targeting hospitals, prescribers, and lab managers with an inside-sales/call-center patient support infrastructure administered through Innomar Strategies (covering reimbursement navigation, infusion logistics, and pharmacy coordination). Customer segments span provincial and federal healthcare payers, clinical laboratories, hospital diagnostic departments, prescribers treating specialty conditions, and patients living with diabetes; major institutional relationships include the Alberta Cancer Foundation (joint $4.5M Precision Analytics Program with Pfizer and Alberta Innovates) and multiple provincial drug formularies. Pricing is not publicly disclosed and is negotiated case by case through public reimbursement channels and direct enterprise contracts.

Name

Roche Canada

Legal name

Hoffmann-La Roche Limited

Website

https://rochecanada.com

Company type

Private

Founded year

1896

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Roche Canada is the Canadian subsidiary of F. Hoffmann-La Roche Ltd, developing and commercializing innovative pharmaceuticals (oncology, ophthalmology, neuroscience, immunology) and a broad in vitro diagnostics portfolio (cobas platforms, point-of-care, sequencing) for hospitals, provincial payers, and patients in Canada.

Ownership category

akta.pro rank

Product category

Pharmaceuticals and In Vitro Diagnostics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Type 1 Diabetes Care (HLAKADAB), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)

Keywords

• Pharmaceutical products
• In vitro diagnostics
• Diabetes management
• Oncology therapeutics
• Diagnostic instruments

Headquarters

HQ city

Mississauga

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Products: Roche Canada (Hoffmann-La Roche Limited) develops, manufactures, and sells innovative prescription medicines across oncology, immunology, infectious diseases, neuroscience, ophthalmology, and other therapeutic areas. Revenue is generated through direct sales to hospitals, pharmacies, and healthcare providers, with public reimbursement through provincial drug programs and private insurers.
2. In Vitro Diagnostic Solutions: Roche Diagnostics develops and sells diagnostic instruments, reagents, and consumables to laboratory customers (hospitals, reference labs, point-of-care settings). Revenue comes from instrument sales, reagent contracts, and service agreements. Products span clinical chemistry, immunochemistry, molecular diagnostics, hematology, pathology, and point-of-care testing.
3. Diabetes Care (Accu-Chek / mySugr): Roche Diabetes Care sells glucose monitoring devices, test strips, insulin delivery accessories, and digital health apps under the Accu-Chek and mySugr brands. Revenue is generated through product sales to patients, pharmacies, and healthcare institutions, with connected digital solutions enhancing patient engagement and device stickiness.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

Roche Canada develops, manufactures, and markets innovative prescription pharmaceuticals across oncology, immunology, neuroscience, ophthalmology, infectious diseases, and rare diseases, and operates an in vitro diagnostics business supplying high-throughput laboratory analyzers, reagents, point-of-care testing systems, and digital health solutions. Diabetes care under the ACCU-CHEK and mySugr brands delivers glucose monitoring hardware and digital diabetes management apps. Patient support programs provide reimbursement navigation, infusion support, and pharmacy coordination for specialty therapies.

Product overview

Roche Canada operates as a diversified healthcare company combining pharmaceuticals, diagnostics, and diabetes care. The pharmaceutical portfolio includes major brands such as HERCEPTIN, AVASTIN, ACTEMRA, OCREVUS, TECENTRIQ, and newer treatments like ITOVEBI for breast cancer, VABYSMO for ophthalmology, and TNKASE for stroke. The diagnostics business centers on the cobas integrated solutions platforms (cobas pro for high-volume and cobas pure for space-constrained labs), supplemented by point-of-care systems including CoaguChek coagulation meters, ACCU-CHEK Inform II blood glucose meters, and cobas b 101 for HbA1c/lipids. Molecular diagnostics feature the cobas Liat PCR system for decentralized testing and Sequencing Solutions for next-generation sequencing. Digital health offerings include the navify Portfolio for clinical decision support and mySugr app for diabetes management. Patient support programs provide reimbursement navigation, infusion support, and pharmacy services across therapeutic areas.

Differentiator

Problem solved

Functional benefit

Brands

• Accu-Chek: Brand for blood glucose monitoring systems and diabetes management solutions under Roche Diabetes Care.
• mySugr
• cobas
• RocheProPlus
• VABYSMO
• TNKase
• Itovebi
• navify

Products and services

• ITOVEBI (inavolisib) Prescription pharmaceutical indicated for adults with advanced HR-positive, HER2-negative breast cancer with a PIK3CA mutation; first therapy funded through Ontario's FAST program. The Itovebi regimen more than doubled median progression-free survival versus standard treatment alone in clinical trials.
• VABYSMO (faricimab) Monoclonal antibody injection for ophthalmology treating neovascular age-related macular degeneration, diabetic macular edema, and macular edema due to retinal vein occlusion, available as pre-filled syringe and publicly funded through Ontario Drug Benefit Program.
• TNKASE (tenecteplase) Thrombolytic agent approved by Health Canada for treatment of acute ischemic stroke in adults, demonstrating comparable safety and efficacy to alteplase in the AcT trial conducted across Canadian stroke centres.
• cobas pro integrated solutions High-volume integrated clinical chemistry and immunochemistry platform combining cobas c, cobas ISE neo, and cobas e 801 modules for laboratory automation, with automated maintenance, continuous reagent loading, and up to 2000 tests/hour clinical chemistry throughput using standardized reagents.
• cobas pure integrated solutions Compact integrated clinical chemistry, immunochemistry, and ISE testing platform on a 2m2 footprint consolidating over 230 test parameters for space-constrained laboratory settings.
• cobas i 601 Mass Spectrometry Analyzer Fully automated, random-access, software-controlled clinical mass spectrometry analyzer integrating sample preparation, liquid chromatography, and tandem mass spectrometry (triple quadrupole with ESI ionization) on a single platform within cobas pro integrated solutions, supporting steroid hormones, vitamin D, therapeutic drug monitoring, and toxicology at up to 100 injections per hour with 48 reagent positions.
• cobas Liat Point-of-Care PCR System Point-of-care molecular PCR system generating high-quality results in 20 minutes or less with an evolving test menu (cobas CT/NG, CT/NG/MG, SARS-CoV-2, Influenza A/B & RSV, Strep A, Cdiff), connected via cobas POC Operations and navify Integrator for centralized management of decentralized testing environments.
• CoaguChek XS / XS Pro Portable point-of-care coagulation meter measuring prothrombin time and INR from a single drop of blood in under one minute, used for professional testing and patient self-testing with bidirectional cobas IT 1000 connectivity and no heparin interference at therapeutic concentrations.
• ACCU-CHEK Inform II Hospital-grade wireless blood glucose meter with 0.6 microlitre sample volume and 5-second results, featuring bidirectional cobas IT 1000 connectivity enabling real-time analysis and patient monitoring through electronic medical records.
• cobas b 101 Compact point-of-care analyzer for HbA1c and lipid panel testing outside laboratory settings, approved in Canada for diabetes and dyslipidemia diagnosis and monitoring.
• ACCU-CHEK Global brand of blood glucose monitoring systems and diabetes management products (meters, test strips, insulin delivery accessories) sold through Canadian retail pharmacies and the accu-chek.ca website as part of Roche's Integrated Personalized Diabetes Management (iPDM) open ecosystem.
• mySugr Digital diabetes management app for people living with diabetes that complements ACCU-CHEK devices for logging, tracking, and therapy insights within Roche's integrated personalized diabetes management ecosystem.
• navify Digital Solutions Portfolio Suite of digital solutions designed to enhance clinical decision-making, workflow efficiency, and operational excellence in healthcare settings, providing data integration and analysis tools across the cobas and cobas Liat installed base via cobas IT 1000 and navify Integrator.
• Roche Sequencing Solutions Unifying next-generation sequencing offerings that cover the entire laboratory workflow from sample isolation and preparation through sequencing technologies to bioinformatics for genetics, oncology, and other clinical research applications.
• Patient Support Programs Programs administered through toll-free call centers and dedicated program administrators (e.g., Innomar Strategies) providing reimbursement navigation, infusion and injection support, pharmacy coordination, and ongoing patient support across oncology, immunology, neuroscience, ophthalmology, and rare disease therapeutic areas for Canadian patients on Roche specialty therapies.

Quantifiable outcome

• Itovebi regimen more than doubled median progression-free survival compared to standard treatment alone in clinical trials for advanced HR-positive, HER2-negative breast cancer with PIK3CA mutation
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

Feature9 records

Partnerships

Five partnerships are on record, tiered flagship and core.

• Pfizer CanadaflagshipStrategic or Co-development Partner · 5 March 2026Pfizer joined a $4.5-million initiative alongside Roche Canada, Alberta Innovates, and the Alberta Cancer Foundation to advance cancer care in Alberta through the Precision Analytics Program. The program leverages one of the world's most complete collections of cancer data to virtually model the provincial cancer system and develop solutions to reduce wait times and improve patient outcomes.
• Alberta InnovatesflagshipStrategic or Co-development Partner · 5 March 2026Alberta Innovates co-funded a $4.5-million precision analytics initiative with Roche Canada, Pfizer, and the Alberta Cancer Foundation to advance cancer care in Alberta. The program was first announced in 2024 and aims to address a projected 56% rise in cancer diagnoses by 2040 through predictive analytics.
• Alberta Cancer FoundationflagshipStrategic or Co-development Partner · 5 March 2026The Alberta Cancer Foundation serves as the lead organization for the $4.5-million Precision Analytics Program, contributing funds alongside Roche Canada, Pfizer, and Alberta Innovates. The program leverages over 300 million patient visits recorded since 2014 to virtually model Alberta's cancer system and develop solutions to reduce wait times and improve outcomes.
• GovLab.aicoreTechnology or Integration · 5 March 2026GovLab.ai is a technology partner in the Alberta Cancer Foundation's Precision Analytics Program, contributing predictive analytics capabilities to the initiative that leverages over 300 million patient visits of cancer data to virtually model Alberta's cancer system.
• AltaMLcoreTechnology or Integration · 5 March 2026AltaML is a technology partner in the Alberta Cancer Foundation's Precision Analytics Program, contributing machine learning and AI capabilities alongside GovLab.ai to develop solutions for reducing cancer wait times and improving patient outcomes in Alberta.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Siemens Healthineers Canada: Siemens Healthineers Canada competes with Roche across in vitro diagnostics, hematology, and laboratory automation with its Atellica and Advia platforms, making it a broad-incumbent rival for hospital laboratory contracts in Canada.
• Abbott Diagnostics Canada: Abbott Canada is the most direct broad incumbent in Roche Diagnostics' core laboratory and immunoassay business, fielding the Architect and Alinity platforms that compete with cobas pro and cobas pure in Canadian hospitals and reference labs.
• Johnson & Johnson Innovative Medicine Canada: J&J Canada is a broad incumbent competitor with overlapping pharma franchises in oncology, immunology, and neuroscience, plus medical devices and consumer health, making it a multi-segment competitive force rather than a single-niche peer.

Direct peers

• Novartis Pharmaceuticals Canada: Novartis Canada is a direct peer in branded pharmaceuticals across oncology, ophthalmology, immunology, and neuroscience, competing head-to-head for provincial formulary listings and specialist prescriber share. Both companies invest heavily in Canadian real-world evidence and patient support programs.
• Sanofi Canada: Sanofi Canada is a direct peer in specialty pharmaceuticals (immunology, oncology, rare disease) and consumer health, operating with the same field-sales and reimbursement-navigation model across Canadian provinces.
• Merck Canada: Merck Canada is a direct peer in oncology (KEYTRUDA competes with TECENTRIQ), vaccines, and specialty medicines, and uses a comparable enterprise sales motion targeting Canadian hospitals, payers, and specialists.
• Bristol-Myers Squibb Canada: BMS Canada competes directly with Roche in immuno-oncology (Opdivo vs Tecentriq) and hematology, sharing the same specialty pharmacy and patient support program infrastructure for high-cost oncology biologics in Canada.
• AstraZeneca Canada: AstraZeneca Canada is a direct peer across oncology, rare disease, and cardiovascular/metabolic therapy areas, with a parallel focus on Canadian clinical trials and provincial reimbursement through the pan-Canadian Pharmaceutical Alliance.
• Pfizer Canada: Pfizer Canada is a direct peer with overlapping innovative pharmaceutical portfolios in oncology and rare disease and an active co-development partner of Roche Canada in the Alberta Precision Analytics Program. Both operate with similar Canadian field-sales and patient-support GTM models.
• Bayer Canada: Bayer Canada is a direct peer in pharmaceuticals (oncology, cardiology, women's health) and radiology/contrast imaging, sharing similar GTM patterns into Canadian hospitals and provincial formularies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/rochecanada
• YouTubeyoutube.com/roche
• Facebookfacebook.com/roche
• LinkedInlinkedin.com/company/roche-canada
• Instagraminstagram.com/roche

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche Canada